BEF, Author at The Boomer Esiason Foundation

March 19, 2019

SOURCE: LA TIMES Using soil from a grassy field in Maine and a miniaturized diffusion chamber, scientists have cultivated a microbe that could help tame the spread of antibiotic-resistant superbugs. When tricked into growing in a lab, the microbe makes a compound that kills strains of tuberculosis,...

CFF Announces Unprecedented Acceleration and Expansion of CF Research, Care and Patient Programs

by BEF

CF Community, CF News, Research

March 19, 2019

SOURCE: CFF.org The Cystic Fibrosis Foundation today announced an unprecedented acceleration and expansion of its research, care and patient programs for the CF community. This action is possible as a result of the sale of the Foundation’s royalty rights to CF treatments developed by Vertex Pharmaceuticals...

Vertex Submits Application for Combination Drug for People with 2 Copies of F508del Mutation

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE - VERTEX OFFICIAL PRESS RELEASE November 5, 2014 Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation -U.S. submission includes request for Priority Review; Accelerated Assessment has...

FDA Recommends Approval of KALYDECO for Use in People with CF R117H Mutation

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE: VERTEX PRESS RELEASE FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration's Pulmonary Allergy Drugs...

Median Age Of Survival For Canadians With CF Surpasses 50 via CF News Today

by BEF

CF News, Research, Therapies

March 19, 2019

SOURCE In the 1980s, life expectancy for persons with cystic fibrosis (CF) was just 12 years in the US, and around 20 in Canada. However, the median age of survival for Canadian CF patients continues on an upward trend, and is currently estimated to be 50.9...

UNC Researchers Find New CF Drugs Counteract One Another’s Effectiveness via CF News Today

by BEF

CF News, Research, Therapies

March 19, 2019

SOURCE Findings of new study led by Martina Gentzsch, PhD, at the University of North Carolina School of Medicine and the UNC Marsico Lung Institute in Chapel Hill, N.C. could help drug developers improve compounds designed to correct CFTR proteins in cystic fibrosis (CF) patients. In...

Vertex’s Two-Drug Cystic Fibrosis Treatment Shows Promise in Clinical Trials via NY Times

by BEF

CF News, Research, Therapies

March 19, 2019

Vertex Pharmaceuticals said on Tuesday that a combination of two of its drugs had successfully treated cystic fibrosis in closely watched clinical trials, potentially clearing the way for approval of a new option for nearly half the patients with the genetic disease. The drug combination, when...

Vertex Announces Presentation of New KALYDECO™ (ivacaftor) Data via Market Watch

by BEF

CF News, Research

March 19, 2019

Via Source: Marketwatch.com New data showed that KALYDECO reduced the loss of lung function by half over 3 years in people with CF who have the G551D mutation compared to similar untreated patients--New data from rollover study of ivacaftor in people with the R117H mutation support...

Aptalis Pharma Studies Panzytrat in Cystic Fibrosis Patients in Phase 4 Trial via CF News Today

by BEF

CF News, Research, Therapies

March 19, 2019

via Cystic Fibrosis News Today Aptalis Pharma continued to evaluate its pancreatic enzyme products (PEPs) in patients with cystic fibrosis and exocrine pancreatic insufficiency in its Phase 4 clinical trial of Panzytrat® 25,000. Results show that patients taking Panzytrat had better control over their steatorrhea, or...

Pancreatic Enzyme Products May Benefit Cystic Fibrosis Patients with Malabsorption via CF News Today

by BEF

CF News, Research, Therapies

March 19, 2019

Via Cystic Fibrosis News Today After the Food and Drug Administration (FDA) issued rules requiring approval of pancreatic enzyme products (PEPs) in 2004, the cost and availability of the products added another hardship to the lives of cystic fibrosis patients, some of whom use PEPs to...

Author: BEF

New antibiotic teixobactin kills drug-resistant superbugs, study says via LA Times

CFF Announces Unprecedented Acceleration and Expansion of CF Research, Care and Patient Programs

Vertex Submits Application for Combination Drug for People with 2 Copies of F508del Mutation

FDA Recommends Approval of KALYDECO for Use in People with CF R117H Mutation

Median Age Of Survival For Canadians With CF Surpasses 50 via CF News Today

UNC Researchers Find New CF Drugs Counteract One Another’s Effectiveness via CF News Today

Vertex’s Two-Drug Cystic Fibrosis Treatment Shows Promise in Clinical Trials via NY Times

Vertex Announces Presentation of New KALYDECO™ (ivacaftor) Data via Market Watch

Aptalis Pharma Studies Panzytrat in Cystic Fibrosis Patients in Phase 4 Trial via CF News Today

Pancreatic Enzyme Products May Benefit Cystic Fibrosis Patients with Malabsorption via CF News Today

Never miss an update. Subscribe to our emails!